GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
translation-mRNA display selection platform. These cyclic peptides show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state and block Ras-Raf interaction. A co-crystal structure of peptide KD2 with K-Ras(G12D)·GppNHp reveals that this peptide binds in the Switch II groove region with concomitant opening of the Switch II loop and a 40° rotation of the α2 helix, and that a threonine residue (Thr10) on KD2 has direct access to the mutant aspartate (Asp12) on K-Ras. Replacing this threonine with non-natural amino acids afforded peptides with improved potency at inhibiting the interaction between Raf1-RBD and K-Ras(G12D) but not wildtype K-Ras. The union of G12D over wildtype selectivity and GTP state/GDP state selectivity is particularly desirable, considering that oncogenic K-Ras(G12D) exists predominantly in the GTP state in cancer cells, and wildtype K-Ras signaling is important for the maintenance of healthy cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, these compounds have no discernable effect on wild-type KRAS, exemplifying the distinct features of the GTP-bound state of KRAS mutants174.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These include DARPins [71], cyclic peptides [72], KRAS–RAF protein–protein interaction inhibitors [73], and KRAS–GAP molecular glue-based approaches [74].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [72]
In the citing paper
“In 2020, Zhang et al.174 identified three cyclic peptide ligands that are unique in that they bind preferentially within the switch 2 groove of KRASG12D-GTP and inhibit its interaction with RAF proteins.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
In the citing paper
“cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Self-citationMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
Cited by
Items 101–129 of 129
Mechanistic Insight on Ras Inhibition Strategies in Cancer Therapy
Anoosheh, J. P., Barzegar, A., Hejazi, M. S., Hasheminejad, N., Heidari, H. R., & Aghdam, E. M. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.25
“Most recently, Zhang and colleagues developed cyclic peptides based on the Ras-Raf binding site.(52) The peptides show selective Inhibition of K-Ras (G12D) in GTP form over the wild-type K-Ras.”
BackgroundKRAS G12D can be targeted by potent salt-bridge forming inhibitorsPreprint
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J. W., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.13.472365
Targeting a broad spectrum of KRAS -mutant cancers by hyperactivation-induced cell deathPreprint
Lilja, J., Kaivola, J., Conway, J. R. W., Vuorio, J., Parkkola, H., Roivas, P., Varila, T., Jacquemet, G., Peuhu, E., Wang, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.21.508660
Research Progress of Antitumor Small Molecule Inhibitor Targeting SOS1
黄, 景. (2023) · World Journal of Cancer Research · doi:10.12677/wjcr.2023.132014
Hu, Z., & Martı́, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.15.567238
A Review of the in Silico Design and Development Approaches of Ras-Specific Anticancer Therapeutics
Motiei, P., Heidari, H. R., Hejazi, M. S., Molavi, O., & Aghdam, E. M. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10578-3
“The rigidification of the cyclic peptide scaffold was considered to enhance the activity of the selected peptide (Zhang et al. 2020).”
A Quantum Computing Pipeline for Real World Drug Discovery: From Algorithm to Quantum HardwarePreprint
Li, W., Yin, Z., Li, X., Ma, D., Yi, S., Zhang, Z., Zou, C., Bu, K., Dai, M., Yue, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.08.574600
Self-citationKidane, M., Hoffman, R. M., Wolfe-Demarco, J. K., Huang, T.-Y., Teng, C.-L., Lira, L. M. G., Lin‐Jones, J., Pallares, G., Lamerdin, J. E., Servant, N. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.20.604418
Alshahrani, M., Parikh, V., Foley, B., Hu, G., & Verkhivker, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.11.642708
Watanabe, Y., Tezuka, C., Nobusawa, K., & Takahashi, T. (2025) · Chemical Communications · doi:10.1039/d4cc06138a
Nii, K., Ebihara, A., Morimasa, Y., & Tamiya, M. (2025) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202500239
Rajitha Rajeshwar, T., Lagergren, J. H., Smith, J. C., & Demerdash, O. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.12.011
The effect of peptide size on target affinity in mRNA display-derived macrocyclic peptides
Jing, X., Suh, J., Maxwell, J. W. C., Patel, K., Norman, A. R., Reid, X. J., Deshpande, C. N., Low, J., Payne, R. J., Passioura, T., et al. (2026) · Chemical Communications · doi:10.1039/d5cc06167a
StrEAMM-Thioether: Efficient Structure Prediction for Thioether-Linked Cyclic Peptides
Ho, M. N., Miao, J., Shan, Y., Li, C. Y., Suga, H., Baleja, J., & Lin, Y. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c06368 · Cited by 1
Self-citationAbraham, S., Zhu, C., Le, L. H. S., Alugubelli, Y. R., Nonomura, T., Huang, Y., Hampton, J. T., Zhou, Y., & Liu, W. R. (2026) · Biochemistry · doi:10.1021/acs.biochem.6c00058
Chiyoda, A., Matsuo, A., Yamano, T., & Tanada, M. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00122 · Cited by 1
Mitcheltree, M. J., Boo, N., Boyer, N. C., Brown, Z. Z., Chai, X., Duggal, R., Garrigou, M., Hayes, R. P., Johnston, J. M., Josien, H. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726527
“Notably, all known phage-and mRNA-display screens generating KRAS isoform-selective macrocyclic peptides to date have yielded SII-P binders, 4,17,18 reinforcing the reputation of this pocket as perhaps the only site to which selective and functional KRAS ligands might be identified.”
Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer
Nguyen, H. T. N., Le, B. H. N., Van, N. T. H., Tran, T. T. T., & Nguyen, T. M. (2026) · Pharmaceuticals · doi:10.3390/ph19070998
“Even when internalized, typically via macropinocytosis, peptides are frequently sequestered within endosomal compartments and fail to access their cytosolic targets [110].”
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
“Unlike PROTACs, these approaches do not rely on the ubiquitin-proteasome system and primarily function through direct inhibition of KRAS activity rather than degradation [244, 245].”
Self-citationPeptide-protein interactions in drug discovery
Ying, H., Lei, Y., Luo, Y., Zeng, J., & de la Fuente‐Núñez, C. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100598
BindingDB Entry 50014692: Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor.
BindingDB (2022) · UC San Diego · doi:10.7270/q22v2kz6
BindingDB Entry 50015977: Cyclic Peptide Screening Methods for Preclinical Drug Discovery.
BindingDB (2023) · UC San Diego · doi:10.7270/q24q7zzw
BindingDB (2026) · UC San Diego · doi:10.7270/q26w9gxr
BindingDB (2026) · UC San Diego · doi:10.7270/q2t4401d
Structural and Energetic Determinants of Monobody Recognition of Oncogenic KRAS Variants
Kumar, A., & Huang, Y. M. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c04965 · Cited by 1
Metadata
- Authors
- Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H.
- Affiliations
- Howard Hughes Medical Institute (US)
- The University of Tokyo (JP)
- Corresponding author
- Shokat, Kevan M.
- Suga, Hiroaki
- ORCID
- Venue
- ACS Central Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-09-23
- Volume
- 6
- Issue
- 10
- Pages
- 1753-1761
- ISSN
- 2374-7943 (ISSN-L)
- 2374-7951
- PMC
- PMC7596874
- OpenAlex
- W3089129315
- Cited by
- 124
- References
- 47
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 25 · 2023: 20 · 2022: 22 · 2021: 25 · 2020: 1
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- ACS Central Science (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (1R01CA244550)
- Damon Runyon Cancer Research Foundation (DRG-2229-15, DRG-2281-17)
- Samuel Waxman Cancer Research Foundation
- Mark Foundation For Cancer Research (SU2C)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12D, Raf, Ras-Raf interaction, cyclic peptide ligands, unnatural amino acids, oncogenic Ras
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.